Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibrutinib + R-CHOEP
- Development stage
- Unknown
- Lead developer
- Janssen Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination regimen consists of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib added to the standard R-CHOEP chemotherapy backbone, which includes rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone. Investigated by the University Hospital Muenster, this regimen is specifically designed for younger, high-risk patients with diffuse large B-cell lymphoma (DLBCL). Ibrutinib works by irreversibly binding to BTK, thereby inhibiting B-cell receptor signaling pathways that drive malignant B-cell proliferation. The R-CHOEP component provides a multi-modal cytotoxic attack: rituximab targets CD20-positive B-cells for immune-mediated destruction, while the chemotherapy agents induce DNA damage and disrupt microtubule assembly to trigger apoptosis.
- Brand names
- ImbruvicaRituxan
- Other names
- Ibrutinib + R-CHOEP-14Ibrutinib-R-CHOEPR-CHOEP-14 + ibrutinib
02
Targets
CD20 (B-lymphocyte antigen CD20)BTK (Bruton tyrosine kinase)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ibrutinib + R-CHOEP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibrutinib + R-CHOEP.